NuMedii Incorporated, a next generation biopharma company, announced yesterday that it has named Heather Arnett, PhD as its new vice president, Research.

Arnett is leading research discovery and early development at NuMedii based on the company's Artificial Intelligence Drug Discovery technology, which enables the discovery of novel targets and precision drug candidates across a number of therapeutic areas including inflammation, oncology and rare diseases like idiopathic pulmonary fibrosis. She has more than 15 years' experience in large and small molecule drug discovery and development, and more than 30 publications in top-tier journals with research focused on diverse pathways in immunology, neuroscience and fibrotic diseases. Prior to joining NuMedii, she was director of Research at Amgen where she spearheaded multiple immune modulatory therapy programs.

Gini Deshpande PhD, chief executive officer, NuMedii, said, 'We are thrilled to have Heather join NuMedii in this vital role at this important time as we advance our development program to successfully translate AI hits into novel therapeutics. With her breadth of expertise in the discovery and development of large and small molecules, particularly in inflammation, fibrosis and immuno-oncology, Heather will play a critical role in helping us fulfil our mission of developing new therapies for patients with unmet medical needs, such as those with IPF, a fatal lung disease.'